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Preventing Cervical Cancer in the 
United States: Barriers and 
Resolutions for HPv vaccination
Anna Louise Beavis* and Kimberly L. Levinson
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Hospital, 
Baltimore, MD, USA
Human papillomavirus (HPV) vaccination rates for preadolescent and adolescent girls 
in the United States are far behind those of other developed nations. These rates dif-
fer substantially by region and state, socioeconomic status, and insurance status. In 
parents and young women, a lack of awareness and a misperception of the risk of this 
vaccine drive low vaccination rates. In physicians, lack of comfort with discussion of 
sexuality and the perception that the vaccine should be delayed to a later age contribute 
to low vaccination rates. Patient- and physician-targeted educational campaigns, sys-
tems-based interventions, and school-based vaccine clinics offer a variety of ways to 
address the barriers to HPV vaccination. A diverse and culturally appropriate approach 
to promoting vaccine uptake has the potential to significantly improve vaccination rates 
in order to reach the Healthy People 2020 goal of over 80% vaccination in adolescent 
girls. This article reviews the disparities in HPV vaccination rates in girls in the United 
States, the influences of patients’, physicians’, and parents’ attitudes on vaccine uptake, 
and the proposed interventions that may help the United States reach its goal for vaccine 
coverage.
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iNTRODUCTiON
Nearly 13,000 American women will be diagnosed with cervical cancer in 2015, and over 4,000 
women will die from cervical cancer (1). With the introduction of regular Papanicolaou (Pap) 
smear screening in the 1950s, cervical cancer incidence rates dropped over 80% (2). While this 
represents a huge public health success, there is potential for even greater impact on this disease 
with the human papillomavirus (HPV) vaccination. HPV is the known necessary cause for cervical 
cancer, and in 2006, the first vaccine targeting HPV was approved in the United States for preven-
tion of both cervical cancer and genital warts. This four-valent vaccine (trade name Gardasil, 
Merck & Co., Inc.) is active against HPV genotypes 6, 11, 16, and 18, which are responsible for 
approximately 66% of cervical cancers and 90% of genital warts. It is administered as three injec-
tions over 6 months (3). In 2006, the Advisory Committee on Immunization Practices (ACIP) 
recommended HPV vaccination as a routine vaccine for girls aged 11–12 and approved it for all 
women up to the age of 26 (4). In 2009, a bivalent vaccine, targeting oncogenic HPV genotypes 16 
and 18 was also approved (trade name Cervarix, GalaxoSmithKline) (4), which was found to be 
similarly efficacious against cervical cancers caused by these HPV genotypes (3). More recently, in 
December 2014, the Food and Drug Administration (FDA) approved a nine-valent vaccine (trade 
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name Gardasil 9, Merck & Co., Inc.) that covers five additional 
HPV genotypes (31, 33, 45, 52, and 58), which are responsible 
for an additional 15–20% of cervical cancer cases (5). Soon after, 
in February 2015, the ACIP incorporated the nine-valent vac-
cine into its recommendations for routine recommendation as 
an alternative to the four- and bivalent HPV vaccines (6). Phase 
III trials of the newest vaccine show over 95% efficacy against the 
additional HPV genotypes (5); therefore, vaccinating the next 
generation of young women has the potential to prevent almost 
90% of cervical cancer cases.
The development of a vaccine against HPV was a major break-
through in science, but its potential public health success heavily 
depends upon the acceptance and uptake in any given population. 
Compared to other developed nations, the United States has been 
slow to vaccinate. In the first year after the vaccine was approved, 
only 11.6% of American girls aged 13–17 received at least one 
dose (7), in contrast to over 80% of girls aged 13–17 who initiated 
vaccination in Australia (8). One of the key differences between 
these two countries is the way in which Australia approached 
the public health need: a successful nationwide, school-based, 
government-funded HPV vaccination campaign was launched 
in 2007 (8). While it is too early to show reductions in cervical 
cancer rates in those vaccinated, the prevalence of genital warts 
in Australian women under 21 years of age has dropped over 90% 
in the last 5 years, compared to no change in the rates for women 
over the age of 30, who did not receive vaccine (9).
Since 2007, vaccine uptake rates have improved in the United 
States. However, they are still well below goal. Two recent national 
surveys estimated that between 34 and 60% of eligible girls of 
ages 11–26 years have received at least one dose of the vaccine 
(i.e., vaccine uptake), and fewer than half complete the entire 
three dose regimen (i.e., vaccine completion) (7, 10). Healthy 
People 2020 has set a goal to reach 80% vaccine completion 
in girls aged 13–15 by the year 2020 (11). In order to achieve 
this, vaccination rates will need to more than double in the next 
5 years. Understanding the country-specific factors behind the 
low vaccination rates will help inform interventions to improve 
uptake in the United States.
In this review, we will evaluate the recent research in dis-
parities in vaccine uptake in the United States, examine key 
stakeholders’ attitudes toward the vaccine, and consider potential 
interventions that may help improve vaccination uptake rates in 
the United States. While this vaccine has been approved and is 
recommended for boys as well (4), this review will focus on the 
available research for vaccination in girls.
NOTABLe DiSPARiTieS iN HPv 
vACCiNATiON
In the United States, cervical cancer disproportionately affects 
women of low socioeconomic status, minority populations, and 
those with limited access to the health-care system (12, 13). The 
racial disparities may be even more pronounced than previously 
thought (14). Differences in HPV vaccination initially paralleled 
these same racial and socioeconomic disparities, but recent data 
suggest that racial and socioeconomic disparities have decreased 
significantly (15). However, differences in vaccine uptake are 
still pervasive by region, insurance status, and sexual orientation 
(16–19).
Regional Differences
Human papillomavirus vaccination rates vary widely by state. In 
2009, HPV vaccination initiation was highest for the Northeast 
and Midwest regions of the United States and lowest in the 
Southeast (20). Additionally, family physicians located in the 
South less routinely offer the vaccine when compared to family 
physicians in the Northeast, Midwest, and West regions of the 
United States. These differences were not seen among pediatri-
cians, who have high rates of vaccine delivery nationwide. This 
may be due to pediatricians’ emphasis on immunization in their 
education and scope of practice, as pediatricians were also more 
likely to participate in the Vaccines for Children Program, a 
federally funded immunization program. Family physicians are 
also historically slower to incorporate any vaccine recommenda-
tion compared to pediatricians (21). The National Immunization 
Survey-Teen (NIS-Teen), an annual survey used by the Center 
for Disease Control (CDC) to monitor vaccination coverage in 
adolescents, surveyed over 20,000 adolescents in all 50 states and 
the District of Colombia (DC) in 2014 and found that Kansas 
has the lowest state-level HPV vaccine uptake rate: only 38.3% 
of girls aged 13–17 had initiated vaccination, while Rhode Island 
has the highest: 76% of girls aged 13–17 had initiated vaccination 
(10). Unfortunately, the states with the highest cervical cancer 
rates also have some of the lowest HPV vaccination rates (22). 
Figure  1 demonstrates the vast state-wide differences in HPV 
vaccination initiation and completion in girls aged 13–17 dur-
ing 2014 according to the NIS-Teen survey data. These regional 
differences may reflect how much each state’s government has 
chosen to encourage the vaccination. Washington, DC, USA, for 
example, puts resources into both educational interventions and 
mandates the vaccine; likely as a result, the percentage of girls 
receiving at least one dose rose from 38.7% in 2008 to 75.2% in 
2014, second only to Rhode Island (15, 23).
ethnic/Racial Disparities
Minority populations  –  black women and Hispanic women 
specifically – are more likely to be diagnosed with cervical cancer 
(14). HPV also appears to be more prevalent in black women 
compared to all other racial and ethnic groups in the United States 
(25). In the first several years after the HPV vaccine was made 
available, studies reported that young black women were less 
likely to initiate vaccination, and if they did initiate vaccination, 
they were less likely to complete the vaccination series than other 
racial groups (16, 26, 27). Fisher et al. performed a meta-analysis 
of the available data from vaccine inception to March 2012 and 
confirmed this finding [OR 0.89 comparing vaccine initiation in 
non-Hispanic black women to non-Hispanic white women, 95% 
confidence interval (CI): 0.82–0.97] (19).
However, in the more recent literature, estimates of vaccine 
uptake by racial category demonstrate positive change and may 
reflect a rapidly changing landscape of vaccine acceptability 
and accessibility. Data from the 2014 NIS-Teen survey show 
that more non-Hispanic black adolescents received at least one 
FiGURe 1 | Uptake and completion rates of HPv vaccination by state. This graph shows the percentage of female adolescents aged 13–17 who initiated and 
completed the HPV vaccination series in the United States in 2014, by state. HPV vaccination uptake ranges from 76% in Rhode Island to 38.3% in Kansas (15). 
The 10 states with the highest cervical cancer incidence rates according to the CDC in 2012 are marked with *; most are among those with the lowest HPV 
vaccination rates (24). HPV vaccination rates adapted from the NIS-Teen survey data reported in Reagan-Steiner et al., (15). DC, District of Columbia; HPV, human 
papillomavirus.
February 2016 | Volume 6 | Article 193
Beavis and Levinson HPV Vaccination in the United States
Frontiers in Oncology | www.frontiersin.org
dose of the HPV vaccine than their white counterparts (66.4 vs. 
56.2%, p < 0.05). Compared to NIS-Teen data from 2008, where 
vaccine uptake rates of both races was around 35%, these rates 
show improvements in uptake for both groups over time (23). 
However, rates of receipt of all three doses remain low for both 
groups (39 vs. 37.5% non-Hispanic black vs. non-Hispanic white 
women, p-value not given) (15).
It is unclear whether vaccination rates among Hispanic and 
Asian women differ from rates in non-Hispanic white women. A 
systematic review of the studies comparing vaccine rates among 
these groups was inconclusive (19). In the 2014 NIS-Teen survey, 
Hispanic adolescents were both more likely to initiate vaccination 
compared to non-Hispanic whites (66.3 vs. 56.1%, p < 0.05) and 
more likely to have received three doses (46.9 vs. 37.5%, p < 0.05) 
(15). While these data are encouraging and demonstrate a closing 
gap in racial and ethnic disparities, the fact that fewer than half 
of all groups complete the series indicates that there is significant 
room for improvement (21).
Sexual Orientation
While the HPV virus is prevalent in women who have sex with 
women (28), this group of women is less likely to report appro-
priate Pap screening (29). Gay, lesbian, and bisexual women 
or “sexual minority adults” are also more likely to smoke than 
their “non-minority” counterparts (30). Smoking increases the 
chances of HPV-related cervical changes, persistence of HPV 
(31), and progression from cervical dysplasia to invasive cancer 
(32). Therefore, regardless of sexual orientation, national screen-
ing and vaccination recommendations apply and may be even 
more important. However, an analysis of the 2006–2010 National 
Survey of Family Growth (NSFG) found that lesbian women are 
less likely to have initiated HPV vaccination than their hetero-
sexual counterparts (8.5 vs. 28.5%, p = 0.007). In this study, there 
were no differences between bisexual women and heterosexual 
women in vaccine initiation. These percentages should be inter-
preted with caution, as the sample sizes for these subgroups of 
women were small (n = 62 for lesbian women and n = 235 for 
bisexual women); however, the differences among these different 
groups remain concerning (17). A national online survey targeted 
at the lesbian, gay, and bisexual community, which included 543 
gay and bisexual women aged 18–26 found more encouraging 
results: 45% reportedly had initiated the HPV vaccine (18). 
While the NSFG survey may be an underestimation due to its 
small numbers, the online survey may be an overestimation as 
those volunteering to participate in online health surveys may be 
more likely to have received health care and vaccination, and they 
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failed to differentiate between lesbian and bisexual women. Due 
to the small number of other studies addressing vaccine uptake in 
gay and bisexual women, the true percentage of vaccine initiators 
in this group is not known. Given the available data, however, 
vaccine uptake among sexual minority adults appears lower than 
the average of 60% for all American female adolescents aged 
13–17 (10).
Socioeconomic and insurance Status
In the United States, cost is frequently cited as a barrier to HPV 
vaccination initiation and completion (18, 21, 27, 33). Historically, 
women of lower socioeconomic status were less likely to initiate 
and complete the HPV vaccine series (16, 19, 27). In 2008, pedia-
tricians and family practice physicians reported that financial 
concerns were the most frequently cited reasons for not vaccinat-
ing (21). Much of this, however, may be explained by insurance 
status. Women with any insurance in the United States are much 
more likely to have been counseled about the HPV vaccine, are 
more likely to intend to get vaccinated, and are more likely to have 
initiated vaccination than uninsured women (16, 19, 33, 34). A 
meta-analysis demonstrated that lack of health insurance, rather 
than income itself, was one of the most important factors associ-
ated with failure to initiate HPV vaccination (19). This finding is 
very important from a public health perspective, as this plays a 
critical role in determining strategies that could improve vaccina-
tion initiation and completion.
The passage of the Affordable Care Act (ACA) in 2010 is one 
major public health change that is expected to improve HPV vac-
cination. Under the ACA, any person with insurance can receive 
the HPV vaccine without any additional cost sharing (i.e., they do 
not have to pay a copay) when they go to an in-network provider 
(35). If the cost of vaccination is truly a pivotal barrier, a rise in 
vaccine uptake should be seen after the passage of the ACA.
STAKeHOLDeRS’ KNOwLeDGe AND 
ATTiTUDeS TOwARD HPv vACCiNATiON
An understanding of the various stakeholders’ knowledge and 
attitudes about the HPV vaccine is critical to understand why 
vaccination has not been more widely accepted and to help 
inform strategies to improve its uptake.
Parents’ Knowledge and Attitudes
Generally, parents’ knowledge of HPV in the United States is 
poor. In a subset of the National Health Interview Survey 2010, 
4 years after the four-valent vaccine was approved, only 63% of 
5,735 parents of children aged 8–17 had even heard of the HPV 
vaccine (36). Another survey 3  years later failed to show any 
meaningful improvement: 68% of American adults had heard of 
the HPV vaccine (37). Parents who lack knowledge frequently 
cite concerns about side effects and vaccine efficacy as reasons 
not to vaccinate their daughters (21, 38, 39). Some of this lack of 
knowledge may be related to lack of education, which may result 
in failure to vaccinate: mothers with lower education level are 
less likely to have their daughters vaccinated than mothers with 
higher education level (26).
Parents’ attitudes toward their children and the vaccine also 
influence vaccination rates. Parents who perceive their daughter 
to be at low risk of sexual activity often fail to vaccinate their 
daughters (39). Parents are more likely to refuse or delay vac-
cination for girls who are 11–12 years old than for girls who are 
13–15 years old, and concerns about sexual activity, including the 
unfounded concern that receipt of the vaccine will result in risky 
sexual behavior, are associated with these delays (21, 40). Open 
discussion with the physician may help to alleviate these fears and 
change parents’ attitudes regarding vaccination, as parents who 
did not feel they could discuss their concerns with their physician 
were more likely to not vaccinate their child (38). Additionally, 
a mother’s own health practices influence her decisions about 
her daughter: mothers with more exposure to a primary care 
physician who regularly receive preventive care (e.g., Pap smears, 
mammograms) are more likely to agree to vaccinate their 
daughters, perhaps reflecting the value they place in preventive 
medicine (41, 42).
Patients’ Preferences
While over 80% of young women (ages 15–25) have heard of the 
HPV vaccine (17), young women express similar concerns as 
their parents with regards to adverse effects and efficacy (18, 43). 
On the one hand, many girls and women who do not intend to 
get vaccinated cite a perceived low risk for HPV as their reason 
against vaccination. On the other hand, young women who 
report that they do intend to get vaccinated are more likely to have 
already had sex, when the timing of the vaccination is less ideal 
(34). Additionally, college-age women are influenced by their 
peers and are more likely to get vaccinated if it is perceived as 
the social norm (44). Most of the studies conducted on patients’ 
attitudes toward the HPV vaccine focused in adolescents and 
adults but few explore the attitudes of 11- to 12-year-old girls who 
would ideally receive the vaccine. One small study did evaluate 
the attitudes of this population and found that 11- to 12-year-old 
girls are interested in information about vaccine efficacy and side 
effects, but a discussion of sexual health was less important to 
both the girls and their mothers (45).
Physician influence
The ACIP recommends HPV vaccine to be given to girls of 
ages between 11 and 12, at the same time as the tetanus– 
diphtheria–acellular pertussis (Tdap) vaccine and the four-
valent meningococcal vaccine (46). However, parents and their 
daughters often rely on the physician to communicate these 
recommendations (45), and lack of physician recommendation 
is one of the most frequently cited reasons for not vaccinating 
preadolescent and adolescent women (38, 43). In a longitudinal 
study of 388 vaccine-eligible girls, only 37% received an HPV 
vaccine recommendation by the physician over the course of a 
year (47). The reason for this extraordinarily low rate of physician 
recommendation is only partially understood. Providers with 
low self-reported vaccination rates report delaying the vaccine 
in patients who they perceive to be at low risk for sexual activity. 
Thus, the ignorance and misconception from the health-care 
provider ultimately drive low vaccination initiation rates. This 
even goes so far that parents of these children report that their 
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doctor supported or even suggested delaying the vaccine (40). In 
contrast, a positive physician recommendation has been shown 
to significantly increase intent to vaccinate (48). In a survey of 
over 17,000 parents of girls of ages 12–17, parents who had been 
counseled by a physician were 23 times more likely to have initi-
ated vaccination and 14 times more likely to complete the series. 
In fact, differences in physician counseling practices may largely 
explain the differences in interstate vaccination rates (16).
The language used in communication also likely has a large 
influence on patients’ decision to vaccinate; approximately 25% 
of family practice physicians and pediatricians reported that they 
do not strongly endorse the vaccine themselves. Therefore, these 
physicians may not recommend vaccination to their patients at 
all, or if they do, the authors of the study suggest that they may 
appear ambivalent and, therefore, their recommendation is less 
likely to be pursued (49). Both pediatricians and family physi-
cians often delay vaccination: they are both almost twice as likely 
to strongly recommend the vaccine to girls aged 13–15 vs. 11–12 
(21). The sensitive nature of the vaccine, as it relates to sexual 
activity, also influences physician comfort discussing the vaccine. 
One study found that almost half of those surveyed felt that it was 
necessary to discuss sexuality before recommending the vaccine 
(21), and vaccine recommendation rates are lower in physicians 
who feel uncomfortable discussing sexuality (49).
iNTeRveNTiONS TO iMPROve DeLiveRY 
OF THe HPv vACCiNe
There are two key themes to the barriers to HPV vaccination in 
the United States, which have been reviewed so far, and which 
much be addressed for any intervention to significantly impact 
uptake rates. First, misinformation and lack of education is 
prevalent among parents, physicians, and young women. Second, 
there has historically been a lack of access to care, either due to 
the cost of the vaccine for those with insurance or under- or 
uninsured status. The ACA created the “Prevention and Public 
Health Fund” which funds “Immunization Grants” provided by 
the CDC to programs, which are designed to improve vaccina-
tion rates (50). There are several different strategies, including 
education-based, systems-based, and region-based interventions 
that have been studied to determine, which might best address 
the current known barriers to vaccination.
educational interventions
Many of the barriers to vaccination which have been described 
above highlight the need for education of all stakeholders: the 
parents, young women, and physicians. However, a recent 
systematic review of educational interventions to improve HPV 
vaccination rates concluded that the widespread implementation 
of educational interventions would be unsuccessful (51). This is 
likely due to the fact that different interventions are necessary to 
reach different communities, and each must be tailored to a spe-
cific audience. Gargano et al. (52) demonstrated the importance 
of understanding and targeting the audience in an intervention 
designed to increase adolescent awareness and interest in HPV 
vaccination. Their first step was a focus group to determine how 
best to reach the target community. They also incorporated the 
HPV education into the already-existent structure of the school 
through the use of the science teacher. By engaging the target 
community, they were able to significantly increase middle and 
high school students’ interest in vaccination through education 
(52). A study targeting Hispanic women first administered a 
survey to ensure the educational material was tailored toward 
the target population’s baseline knowledge and was able to dem-
onstrate significant increase in intention to vaccinate (53). While 
these two studies were successful in increasing interest in vacci-
nation and willingness to vaccinate, other attempts have been less 
successful. An online intervention called “MeFirst” incorporated 
college students’ baseline knowledge of HPV in order to design 
a tailored educational intervention; however, 3 months after the 
intervention, those randomized to the tailored education were 
no more likely to have initiated the vaccine series than those who 
had just read the CDC information face-sheet (54). Of note, few 
studies evaluate actual vaccination uptake outcomes, and most 
rely on changes in reported intention to vaccinate as a surrogate, 
which may over-estimate the impact of education on vaccination 
rates. Given the variability in results of these studies, it is unclear 
what impact educational interventions alone would ultimately 
have on HPV vaccination initiation and completion.
Clinic-Based interventions
Interventions with a systems-based approach have also been 
studied and are encouraged by the CDC as a mechanism to reach 
the Healthy People 2020 goal (10). One type of systems-based 
approach focuses upon intervention at the level of the practice 
and/or clinic. Standing orders, which authorize non-physician 
health-care personnel to administer a vaccine to an individual 
through a protocol approved by an authorized practitioner, are 
one evidenced-based method, which increases vaccination rates 
and is endorsed by the U.S. Preventive Services Task Force (55). 
A survey of young women attending a gynecology clinic found 
that standing orders for the HPV vaccine were generally accept-
able to this population, particularly for the series completion (56).
Automatic reminders or recall-based interventions also 
increase vaccination rates: a systematic review of seven studies 
demonstrated that reminder systems for the parents or patients, 
whether that be through telephone calls, letters, text messages, or 
outreach visits, are consistently effective in improving HPV vac-
cination overall (57). These interventions are also relatively easy 
to implement and may be particularly helpful with improvement 
of vaccine completion rates (58). However, as with the educational 
interventions described above, this type of intervention may not 
work in all groups and may not work if used alone. In one study of 
mostly Hispanic and black parents attending a pediatric clinic in 
Texas, reminder phone calls resulted in improvements in rates of 
receipt of the second and third doses of the HPV vaccine, but only 
in Hispanic populations (59). These results further highlight the 
need to understand the community and culture when initiating and 
evaluating an intervention. Furthermore, the above data support a 
diverse and multifaceted approach to increasing vaccine uptake.
Another systems-based intervention encouraged by the CDC 
targets the physician and combines education, reminders, audits, 
and feedback to help address the physician contribution to low 
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vaccination rates (10). In one cluster randomized controlled 
trial, clinics that received focused clinician education, electronic 
health record based alerts, and quarterly performance feedback 
for physicians had a modest, but statistically significant, increase 
in vaccine initiation compared to control clinics (58). Reminders 
for both parents and physicians can improve vaccination rates, 
and while alone, they will likely not get the United States to the 
Healthy People 2020 goal alone, they are a powerful adjunct to 
any vaccine promotion program.
School-Based interventions
School-based interventions are another type of systems-based 
approach that has been successful in several countries where 
there is already a framework for government-funded universal 
vaccination, such as Australia (8). While many believe that the 
concept of a school-based vaccine clinic is also feasible in the 
United States, some studies suggest that key stakeholders are 
skeptical of this approach. Focus groups in New Mexico were 
conducted with key stakeholders: parents of adolescent girls and 
boys, adolescent girls, middle school nurses, and middle school 
administrators and highlighted their concerns with this type of 
intervention. Overall, parents were uncertain about a middle 
school-based program, and school administrators felt that they 
lacked the implementation authority (60). However, other stud-
ies suggest that this type of intervention can be successful in the 
United States. School-based vaccine clinics seem particularly 
more feasible with the passage of the ACA and no-cost-sharing 
insurance coverage of the vaccine. In a cluster randomized 
controlled trial in Denver (CO, USA) in 2011, 16 schools were 
randomly assigned to a school-based vaccine clinic (n = 8) or a 
control. Clinics were held three times a year to accommodate the 
HPV vaccination schedule. Consent and insurance information 
was collected from the parents prior to vaccine administration. 
Compared to controls, children in the intervention schools 
were more likely to receive the Tdap vaccine, the meningococcal 
vaccine, and the HPV vaccine. The biggest increase was seen in 
HPV vaccination rates, where students were 70% more likely to 
receive the vaccine. One of the issues raised in this study was 
that less than half of the vaccine clinic costs were recuperated 
through insurance claims, although this may be related to their 
study population (over 40% of students were uninsured and were 
not charged for vaccine administration) (61). Regardless, this 
randomized controlled trial provides important evidence that 
school-based vaccine clinics are feasible and can be effective in 
the United States. Additional government funding or partner-
ship with local agencies could help cover costs and, coupled 
with education, stands to have the biggest impact on vaccination 
rates. Furthermore, just as with the other types of interventions 
discussed, adjusting approaches to fit each community or school 
may ultimately be needed in order to gain widespread acceptance.
State- and National-Level interventions
Four of the six jurisdictions (Chicago, DC, Georgia, and Utah) 
which demonstrated improvements in HPV vaccine uptake from 
2013 to 2014 had received funding through Prevention and Public 
Health Fund and had instituted a variety of interventions ranging 
from education to monetary support for vaccine programs (15). 
In addition to funding, state mandates may also have the potential 
to improve vaccination rates. Until recently, only two states had 
instituted a mandate for HPV vaccination. In 2008, Virginia 
passed a mandate for all girls entering the sixth grade to have at 
least one HPV vaccine, and in 2009, Washington, DC, USA, passed 
a similar mandate (15). Both included the ability to “opt-out” at 
parental discretion. These two states now have widely disparate 
rates of vaccine initiation, demonstrating the variability in the 
effectiveness of mandates. On the one hand, Washington, DC, 
USA, ranks number 2 for vaccine initiation in girls aged 13–17, 
and as previously mentioned was one of the only six jurisdictions 
to show improvement in vaccination rates from 2013 to 2014. 
On the other hand, Virginia still ranks 28th for vaccine initiation 
(see Figure 1) (15). Focus groups conducted in Virginia revealed 
that its public generally was not ready for the mandate: parents 
felt the government did not have the right to provide parental 
consent, they felt they did not have enough information about the 
new vaccine before the mandate was launched, they distrusted 
the motivations of Merck, and they wanted more education about 
the vaccine before having to make a decision (62).
State mandates may, therefore, be appropriate for some states, 
but not for others. In fact, a total of 24 states have previously 
tried to introduce a mandate into their legislatures, and only 
Virginia, DC, and Rhode Island have been successful in passing 
it into viable law (63). Rhode Island’s state mandate recently went 
into effect on August 1, 2015; it requires both girls and boys to 
have at least one dose of the vaccine to enter seventh grade this 
year, two doses to enter eighth grade by 2016, and three doses to 
enter ninth grade by 2017. In contrast to the DC and Virginia 
mandates, exceptions to vaccination are only made for physician-
documented medical reasons or if it is against the parents’ reli-
gious beliefs (64). It remains to be seen if this mandate will be 
acceptable to the Rhode Island population, but the state currently 
ranks number 1 for vaccine uptake, which may reflect a positive 
attitude and predict acceptance of the vaccine in this population. 
Further research on the effectiveness of these mandates and other 
state-based interventions is needed to understand why particular 
interventions work in some regions and not others. It is unlikely 
that state mandates alone will help the United States reach its 
vaccination goal; lessons from Virginia’s mandate show us that 
education prior to mandate is the key.
Finding the Right intervention
Table 1 provides a matrix demonstrating the various proposed 
interventions and the barriers which they have the potential to 
address. An analysis of 21 HPV vaccination programs imple-
mented in low- and middle-income countries found that tailoring 
the intervention to meet the community’s unique needs is an 
effective method of improving vaccination rates (24). This same 
principle can be applied in the United States, where it is unlikely 
that one intervention will achieve success in all regions and 
states. While education may help address physician, patient, and 
parent attitudes and beliefs, education alone has not been shown 
to improve the HPV vaccination rates enough to reach the 2020 
goal. State mandates, if used alone, merely provide an incentive 
to vaccinate without addressing attitudes and lack of knowledge. 
Therefore, mandates can result in failure when education is 
TABLe 1 | Addressing barriers through interventions: improving HPv vaccination rates.
Barriers to HPv vaccination
Parent/patient 
lack of knowledge
Physician 
bias
Regional 
differences
Follow-up (vaccination 
completion)
Access 
to care
Cost
Interventions
Individual level Parent/patient educational 
interventions
X
Physician educational interventions X
Clinic level Parent/patient reminders and 
recalls
X
Physician reminders and feedback X X
School level School-based vaccine clinics X X X X
School-based vaccine clinics with 
education
X X X X X
State/national 
level
State-based mandates X X
National no cost-sharing coverage 
(ACA)
X X X
This matrix demonstrates potential HPV vaccination interventions at various levels, from individual to national, and the ways in which each intervention interacts with different barriers 
to vaccination. It is clear that there is not one intervention which alone can address all barriers, and a multipronged approach at the individual, clinic, state, and national levels will be 
necessary to reach the Healthy People 2020 goal of 80% vaccine completion in young women.
HPV, human papillomavirus.
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lagging or not included. Reminder systems for physicians and 
patients, similarly, will not improve knowledge, but can help with 
vaccine completion rates. The ACA legislation has helped improve 
access but does not address knowledge or attitudes. Clearly, there 
is no intervention that will alone result in widespread uptake of 
the vaccine. From the available evidence, the optimal interven-
tion would involve a school-based vaccine clinic combined with 
complementary parental and student education, addressing the 
majority of the barriers to vaccination. It is beyond the scope of 
this review to evaluate HPV vaccination uptake in males in the 
United States. However, similar interventions which increase vac-
cination rates in girls would likely work for both sexes if tailored 
toward improving knowledge, access, and acceptability in both 
populations. As vaccination coverage increases for both boys and 
girls, HPV vaccination will become more of a social norm, which 
will help perpetuate further vaccination of generations to come.
CONCLUSiON
The United States has a long way to go to reach the Healthy 
People 2020 goal of HPV vaccine coverage in over 80% of girls 
aged 13–17. The release of the nine-valent vaccine at the time of 
increasing vaccine uptake represents a possible tipping point in 
the fight against cervical cancer and could be the first step in the 
eradication of the HPV-related disease. An understanding of the 
attitudes and points of view of the various stakeholders is the key 
to designing interventions that are tailored to the needs of vari-
ous communities. While education is the key for all, it will likely 
not be enough. Efficient and effective use of the electronic health 
record to remind physicians and parents about when vaccines are 
due is a proven option. Additionally, school-based vaccination 
methods hold the greatest promise here in the United States and 
have proven effective in other developed countries. The CDC 
encourages state and local public health departments to help 
lead HPV vaccination campaigns, to reach out and educate and 
motivate both parents and clinicians on HPV vaccination, and 
to incorporate HPV vaccination into each jurisdiction’s cancer 
control plans (10). State mandates are not enough. It is clear that 
a multifaceted approach is necessary to break down the barriers 
to HPV vaccination that is so prevalent in the United States.
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